Xcell Therapeutics Inc. (KOSDAQ:373110)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,384.00
+14.00 (1.02%)
Aug 12, 2026, 3:30 PM KST

Xcell Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-11,306-10,927-9,543-9,281-8,342-9,038
Depreciation & Amortization
1,6651,7041,6531,5981,5131,019
Loss (Gain) From Sale of Assets
-98.66-98.66130.13-210.5312
Asset Writedown & Restructuring Costs
---154.12--
Loss (Gain) From Sale of Investments
--19.02-2.720.87--
Loss (Gain) on Equity Investments
1.140.81----
Stock-Based Compensation
70.12127.83228.31283.67540.12354.46
Provision & Write-off of Bad Debts
-35.2289.27259.8950--
Other Operating Activities
318.44379.71383.97587.39230.173,453
Change in Accounts Receivable
-180.272.06-31.37-301.81-104.98-133.14
Change in Inventory
-728.1-537.3760.58-178.38-186.23179.52
Change in Accounts Payable
271.591.5946.3843.66-137.29-239.85
Change in Other Net Operating Assets
-617.06-385.34-180.91280.29-808.69-211.69
Operating Cash Flow
-10,639-9,502-6,996-6,784-7,296-4,605
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-189.32-866.72-382.69-224.82-1,179-1,347
Sale of Property, Plant & Equipment
165.05165.05-55-0.45
Sale (Purchase) of Intangibles
-158.37-316.58-437.34-8.83-145.48-49.14
Investment in Securities
2,622-3,771-1,780-3.96-131.88-3.88
Other Investing Activities
-17.64-17.641,3284.06-10-259.51
Investing Cash Flow
2,422-4,807-1,272-178.55-1,466-1,659

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-7001,950350-3,000
Long-Term Debt Repaid
--1,395-3,035-587.44-455.54-759.28
Net Debt Issued (Repaid)
-722.75-695.48-1,085-237.44-455.542,241
Issuance of Common Stock
9,1709,22015,8753,00016.668,092
Other Financing Activities
119.04119.13-0---
Financing Cash Flow
8,5678,64414,7902,763-438.8814,232

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-3.61-5.691,2392.24.662.15
Net Cash Flow
345.65-5,6717,761-4,197-9,1967,971

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-10,829-10,369-7,379-7,008-8,475-5,952
Free Cash Flow Growth
------
Free Cash Flow Margin
-410.05%-532.01%-381.48%-623.58%-830.82%-302.69%
Free Cash Flow Per Share
-817.91-889.87-737.48-792.48-968.02-718.67
Levered Free Cash Flow
-6,794-6,769-5,076-3,926-5,606-6,886
Unlevered Free Cash Flow
-6,792-6,766-5,074-3,924-5,604-6,774

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
350.71280.96343.69284.27209.73104.88
Cash Income Tax Paid
--11.2623.06-8.3111.263.73
Change in Working Capital
-1,254-759.05-105.33-156.23-1,237-405.17